Coronavirus vaccine formulations
US-11253586-B2 · Feb 22, 2022 · US
SARS-CoV-2 subunit vaccine and microneedle array delivery system
US11737974B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11737974-B2 |
| Application number | US-202117538412-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 30, 2021 |
| Priority date | Mar 5, 2020 |
| Publication date | Aug 29, 2023 |
| Grant date | Aug 29, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of vaccinating a patient for SARS-CoV-2, comprising administering to the patient an amount of a composition, by a route of administration effective to induce an immune response to SARS-CoV-2, wherein said composition comprises (a) a fusion polypeptide comprising (i) an immunogenic amino acid sequence of a SARS-CoV-2 spike protein and (ii) a Toll-like receptor agonist domain, and (b) a pharmaceutically acceptable excipient, wherein said Toll-like receptor agonist domain is a polypeptide. 2. The method of claim 1 , wherein the composition is administered to the patient parenterally. 3. The method of claim 1 , wherein the composition is administered to the patient by inhalation or intra-nasally. 4. The method of claim 1 , wherein the composition is administered to or through the skin. 5. The method of claim 1 , wherein the composition is administered to the patient more than once. 6. The method of claim 1 , wherein said Toll-like receptor agonist domain is a Toll-like receptor 3 (TLR3) agonist domain. 7. The method of claim 1 , wherein said Toll-like receptor agonist domain is a Toll-like receptor 4 (TLR4) agonist domain.
Assignees
Inventors
Classifications
- A61K9/0021Primary
Intradermal administration, e.g. through microneedle arrays or needleless injectors · CPC title
Microneedles or microblades · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11737974B2 cover?
- A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0021. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).